Rebound syndrome in two cases of MS patients after teriflunomide cessation

Acta Neurol Belg. 2022 Oct;122(5):1381-1384. doi: 10.1007/s13760-022-01929-w. Epub 2022 Jul 8.

Authors

Pierre Labauge¹, Xavier Ayrignac², Pauline Prin², Mahmoud Charif², Clarisse Carra-Dalliere²

Affiliations

¹ MS Unit, Department of Neurology, Montpellier University Hospital, Univ Montpellier, INSERM, Montpellier, France. labauge@yahoo.fr.
² MS Unit, Department of Neurology, Montpellier University Hospital, Univ Montpellier, INSERM, Montpellier, France.

PMID: 35802339
DOI: 10.1007/s13760-022-01929-w

No abstract available

Keywords: Multiple sclerosis; Teriflunomide.

Publication types

Case Reports
Letter

MeSH terms

Crotonates / adverse effects
Humans
Hydroxybutyrates
Multiple Sclerosis* / drug therapy
Multiple Sclerosis, Relapsing-Remitting* / drug therapy
Nitriles
Toluidines / adverse effects

Substances

Crotonates
Hydroxybutyrates
Nitriles
Toluidines
teriflunomide